Akèy › Kriz Vazo-oklizif
Etid klinik pou Kriz Vazo-oklizif ap rekrite nan Etazini
7 etid pou Kriz Vazo-oklizif ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Ap rekriteFaz 3
Laj 12 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT06439082Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
Ap rekriteFaz 2
Laj 5 a 20 · Tout sèks · Mizajou Sep 2, 2026 · NCT07369024Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT06699849Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07224360Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Ap rekriteFaz 4
6 Months – 100 Years · Tout sèks · Mizajou Jun 8, 2026 · NCT04657822Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Ap rekrite
Laj 6 a 25 · Tout sèks · Mizajou May 18, 2026 · NCT03353584Sickle Cell Improvement: Enhancing Care in the Emergency Department
Ap rekrite
Jiska laj 18 · Tout sèks · Mizajou Aug 14, 2023 · NCT05373771Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.